Clinical Trials Logo

First Relapse/Progression clinical trials

View clinical trials related to First Relapse/Progression.

Filter by:
  • None
  • Page 1

NCT ID: NCT00530140 Recruiting - Follicular Lymphoma Clinical Trials

Idiotypic Vaccination for Follicular Lymphoma Patients

FLIDVAX2006
Start date: October 2007
Phase: Phase 2
Study type: Interventional

Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6 years. The proposed trial offers life-time idiotypic vaccination to all such patients in first relapse/progression who will achieve second (first, in the case of patients who have never achieved complete response following standard first-line treatment) complete response through autologous stem cell transplant prior to vaccination start. The ultimate goal is a cure, defined as a vaccine-maintained complete response lasting both at least 10 years and at least twice as long as each patient's first complete response.